Back to top
more

Eyenovia (EYEN)

(Delayed Data from NSDQ)

$0.53 USD

0.53
575,049

-0.01 (-1.56%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $0.53 0.00 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EYEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Eyenovia, Inc. [EYEN]

Reports for Purchase

Showing records 1 - 20 ( 83 total )

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/19/2024

Company Report

Pages: 7

Clobetasol FDA Approval and MydCombi Define Near-Term Commercial Focus; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/06/2024

Daily Note

Pages: 3

FDA Approval of Clobetasol Propionate Brings Second Approval Under Eyenovia Stewardship; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 10.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/17/2024

Daily Note

Pages: 5

MicroPine Re-Acquisition Brings Development In-House With Optejet Expertise; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 10.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/14/2023

Company Report

Pages: 7

MydCombi Approval Sets Stage For Optejet; Further Mist Delivery Upside; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/10/2023

Industry Report

Pages: 8

Boots on the Ground at AAO’23-KOL Perspectives and Considerations on Therapeutic Ophthalmic Innovations

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

08/18/2023

Daily Note

Pages: 3

APP13007 Brings New Upside to Topical Ophthalmic Platform; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/11/2023

Company Report

Pages: 7

Optejet Goes Commercial With MydCombi-Next Progress For Presbyopia; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/12/2023

Company Report

Pages: 7

Announced MydCombi Approval Provides Validation For Optejet Delivery; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/09/2023

Daily Note

Pages: 4

Making Sense of Optejet Opportunity Following MydCombi FDA Approval; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

04/19/2023

Daily Note

Pages: 4

KOL Perspective and Receptivity to MydCombi-Emphasis on May 8th PDUFA Date

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

04/03/2023

Company Report

Pages: 7

MydCombi 2Q23 PDUFA Can Set Tone for Novel Optejet Delivery; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

12/14/2022

Daily Note

Pages: 4

MydCombi NDA Acceptance Paves Path For Novel Optejet Delivery

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/11/2022

Company Report

Pages: 7

Positive Phase 3 VISION-2 Trial; MydCombi NDA Resubmission Define Optejet Progress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 12.50

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

10/20/2022

Daily Note

Pages: 4

Positive Phase 3 VISION-2 Trial Top-Line; Squinting to Read the Details

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 5.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

10/05/2022

Company Report

Pages: 41

Optejet Optimizing Delivery in Mydriasis, Presbyopia and Beyond; Initiating With Buy Rating and $12 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 50.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for EYEN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/12/2021

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/10/2021

Company Report

Pages: 5

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/01/2021

Company Report

Pages: 6

Possible MydCombi Approval in 2H21; 2020 Financial Results; Raising PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Eyenovia, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/29/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party